Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$11.03 -3.1%	$12.17	$6.25 ▼ $19.22	$318.52M	0.92	261,965 shs	290,561 shs
MBOT Microbot Medical	$2.47 -2.0%	$2.56	$0.82 ▼ $3.38	$91.67M	1.13	1.82 million shs	1.25 million shs
OM Outset Medical	$17.42 -1.0%	$19.25	$5.85 ▼ $62.10	$311.91M	2.15	156,165 shs	319,110 shs
RXST RxSight	$7.35 -0.4%	$13.43	$6.32 ▼ $58.23	$299.90M	1.21	819,103 shs	1.25 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	+0.44%	-4.85%	+1.88%	-7.03%	+56.97%
MBOT Microbot Medical	-1.18%	-4.55%	+4.13%	+1.20%	+135.51%
OM Outset Medical	-2.76%	-14.60%	-7.07%	+59.85%	-73.51%
RXST RxSight	+1.37%	-12.77%	-45.33%	-48.86%	-84.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLPT ClearPoint Neuro	1.7055 of 5 stars	3.5	1.0	1.9	0.8	0.6
MBOT Microbot Medical	2.3037 of 5 stars	3.5	3.0	2.7	0.0	0.6
OM Outset Medical	1.4601 of 5 stars	3.5	1.0	2.2	0.8	0.0
RXST RxSight	2.2718 of 5 stars	4.0	1.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	3.00	Buy	$25.00	126.65% Upside
MBOT Microbot Medical	3.00	Buy	$9.00	264.37% Upside
OM Outset Medical	3.00	Buy	$29.50	69.35% Upside
RXST RxSight	1.91	Reduce	$17.50	138.10% Upside

Current Analyst Ratings Breakdown

Latest MBOT, OM, CLPT, and RXST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/14/2025	OM Outset Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$37.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00
7/9/2025	RXST RxSight	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$25.00 ➝ $9.00
7/9/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/9/2025	RXST RxSight	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/21/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$14.00 ➝ $21.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$31.39M	9.84	N/A	N/A	$0.92 per share	11.99
MBOT Microbot Medical	N/A	N/A	N/A	N/A	$0.17 per share	N/A
OM Outset Medical	$113.69M	2.72	N/A	N/A	$7.49 per share	2.33
RXST RxSight	$139.93M	2.13	N/A	N/A	$6.98 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$18.91M	-$0.76	N/A	N/A	-64.51%	-78.09%	-51.33%	8/6/2025 (Estimated)
MBOT Microbot Medical	-$11.44M	-$0.65	N/A	N/A	N/A	-110.27%	-94.20%	8/13/2025 (Estimated)
OM Outset Medical	-$127.98M	-$29.15	∞	N/A	-98.74%	-143.62%	-37.50%	8/6/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	-17.90%	-9.54%	-8.51%	8/7/2025 (Estimated)

Latest MBOT, OM, CLPT, and RXST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	MBOT Microbot Medical	-$0.08	N/A	N/A	N/A	N/A	N/A
8/7/2025	Guidance Update	RXST RxSight	-$0.0363	N/A	N/A	N/A	$39.78 million	N/A
8/6/2025	Q2 2025	CLPT ClearPoint Neuro	-$0.20	N/A	N/A	N/A	$9.20 million	N/A
8/6/2025	Q2 2025	OM Outset Medical	-$1.76	N/A	N/A	N/A	$29.40 million	N/A
5/21/2025	Q1 2025	MBOT Microbot Medical	-$0.15	-$0.08	+$0.07	-$0.08	N/A	N/A
5/13/2025	Q1 2025	CLPT ClearPoint Neuro	-$0.15	-$0.22	-$0.07	-$0.22	$8.21 million	$8.49 million
5/7/2025	Q1 2025	OM Outset Medical	-$0.97	-$3.66	-$2.69	-$3.66	$27.81 million	$29.75 million
5/7/2025	Q1 2025	RXST RxSight	-$0.03	-$0.03	N/A	-$0.20	$38.74 million	$37.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
MBOT Microbot Medical	N/A	N/A	N/A	N/A	N/A
OM Outset Medical	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	N/A	3.53	2.57
MBOT Microbot Medical	N/A	16.19	16.19
OM Outset Medical	0.57	8.37	6.74
RXST RxSight	N/A	12.68	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
MBOT Microbot Medical	16.30%
OM Outset Medical	N/A
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.97%
MBOT Microbot Medical	4.74%
OM Outset Medical	2.40%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	27.99 million	26.04 million	Optionable
MBOT Microbot Medical	20	36.38 million	34.65 million	Optionable
OM Outset Medical	520	17.72 million	17.30 million	Not Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable

MBOT, OM, CLPT, and RXST Headlines

Recent News About These Companies

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

July 18 at 1:43 PM | gurufocus.com

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

July 18 at 1:06 PM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ...

July 18 at 12:08 PM | gurufocus.com

RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud ...

July 18 at 10:31 AM | gurufocus.com

RXST INVESTIGATION: RxSight, Inc. (NASDAQ:RXST) 38% Stock Drop Triggers Securities Fraud Investigation – Contact BFA Law if You Lost Money

July 18 at 9:07 AM | globenewswire.com

RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses

July 17 at 12:55 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

July 17 at 10:00 AM | prnewswire.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 16 at 9:00 AM | businesswire.com

Morgan Stanley Downgrades RxSight (RXST)

July 16 at 6:03 AM | msn.com

RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces Investigation into RxSight, Inc. (RXST) and Encourages Investors to Contact the Firm

July 15 at 9:34 PM | globenewswire.com

Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders

July 15 at 5:43 PM | globenewswire.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

July 15 at 3:52 PM | businesswire.com

Morgan Stanley Downgrades RxSight (NASDAQ:RXST) to Equal Weight

July 15 at 9:03 AM | marketbeat.com

RxSight (NASDAQ:RXST) Earns Hold Rating from Jefferies Financial Group

July 13, 2025 | americanbankingnews.com

Brokerages Set RxSight, Inc. (NASDAQ:RXST) PT at $30.20

July 13, 2025 | americanbankingnews.com

RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices ...

July 12, 2025 | businesswire.com

Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced ...

July 12, 2025 | morningstar.comM

RxSight, Inc. (RXST) Investors Who Lost Money - Morningstar

July 12, 2025 | morningstar.comM

Bank of America Cuts RxSight (NASDAQ:RXST) Price Target to $9.00

July 12, 2025 | americanbankingnews.com

RxSight's (RXST) Buy Rating Reiterated at Needham & Company LLC

July 12, 2025 | americanbankingnews.com

RxSight's (RXST) Neutral Rating Reiterated at BTIG Research

July 12, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending

MBOT, OM, CLPT, and RXST Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$11.03 -0.35 (-3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$11.06 +0.04 (+0.32%)

As of 07:59 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Microbot Medical NASDAQ:MBOT

$2.47 -0.05 (-1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.53 +0.06 (+2.43%)

As of 07:50 PM Eastern

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Outset Medical NASDAQ:OM

$17.42 -0.18 (-1.02%)

Closing price 04:00 PM Eastern

Extended Trading

$17.74 +0.31 (+1.81%)

As of 07:15 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

RxSight NASDAQ:RXST

$7.35 -0.03 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$7.45 +0.10 (+1.31%)

As of 07:56 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time